Johnson & Johnson has increased its dividend for the 64th consecutive year, paying $1.34 per share quarterly, reflecting a 3.1% raise. The company maintains a strong financial position with a payout ratio near 48%, supported by robust operating cash flow of $24.53 billion in 2025 against a $12.38 billion dividend payout. Despite competitive pressures on its drug STELARA, JNJ's innovative medicines continue to grow, with sales reaching $25.3 billion in Q2 2026 and adjusted EPS guidance raised for 2026. This steady growth and strong cash flow underpin JNJ's commitment to returning capital to shareholders, making its dividend attractive for income-focused investors.
Johnson & Johnson will report its Q3 2026 earnings on October 13, with analysts expecting earnings per share (EPS) of $2.66, a 5% decline from last year, while revenue is forecasted to grow 5.8% to $25.40 billion. Despite the EPS drop, the company ha...
Four Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, and PepsiCo—continue to deliver steady dividends, crucial for retirees relying on portfolio income. Johnson & Johnson and Procter & Gamble show very safe dividend payouts with health...
Johnson & Johnson announced two-year Phase 3 results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23 receptor 1, showing sustained high skin clearance rates in adults and adolescents with moderate-to-severe plaque psoriasis. Nearly 72% of ...
Five major U.S. companies—Coca-Cola, Procter & Gamble, Johnson & Johnson, PepsiCo, and Realty Income—are highlighted for their long histories of dividend increases and strong cash flow coverage. These firms offer diverse dividend yields, with some pr...
Pfizer offers a dividend yield of 6.24%, much higher than Johnson & Johnson's 2.07%, but Pfizer's payout is frozen and not fully covered by free cash flow, with rising debt and a recent $4.3 billion write-down signaling risk. Johnson & Johnson, despi...
